Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Conserved programmed cell death patterns associate with subtype-specific therapeutic response across multiple cancer types
Zi-Wei Huang, Zi-Han Wang, Yi Liu, Jia-Yi Shen, Yan-Ling Wu, Zi-An Fang, Dong-Hong Wu, Yi-Zhe Cheng, Jing-Jing Zhang, Xiong Zou, Jun Ma, Jiawei Lv, Shuang Wang, Yu-Pei Chen
Zi-Wei Huang, Zi-Han Wang, Yi Liu, Jia-Yi Shen, Yan-Ling Wu, Zi-An Fang, Dong-Hong Wu, Yi-Zhe Cheng, Jing-Jing Zhang, Xiong Zou, Jun Ma, Jiawei Lv, Shuang Wang, Yu-Pei Chen
View: Text | PDF
Clinical Research and Public Health In-Press Preview Cell biology Oncology

Conserved programmed cell death patterns associate with subtype-specific therapeutic response across multiple cancer types

  • Text
  • PDF
Abstract

BACKGROUND. Molecular subtyping may offer a promising path toward a unified framework for precision oncology. We sought to characterize the patterns of programmed cell death (PCD), a pivotal cellular process shaping both intrinsic tumor malignancy and the tumor microenvironment, to better understand tumor heterogeneity. METHODS. We performed integrative multi-cohort transcriptomic analyses encompassing four canonical PCD modes across multiple cancer types. We identified PCD subtypes using nonnegative matrix factorization (NMF), characterized their molecular features and clinical relevance, and developed a streamlined 20-gene classifier to facilitate subtype assignment. RESULTS. We identified five conserved PCD subtypes with distinct genomic alterations, cellular stresses, malignant traits, prognostic outcomes, and immune landscapes. In the immunotherapy setting, PCD subtypes were associated with distinct outcomes across multiple cancer types, with the pyroptosis-dominant (PCD-P) subtype showing the most favorable outcomes. The 20-gene classifier showed good discriminatory performance across independent cohorts. Finally, we proposed candidate subtype-specific therapeutic strategies. CONCLUSION. This study establishes a comprehensive framework for characterizing PCD patterns in cancer, laying the groundwork for biomarker discovery and rational therapeutic design that warrant future evaluation of efficacy and toxicity. FUNDING. National Key R&D Program of China; National Natural Science Foundation of China; Fundamental Research Funds for the Central Universities, Sun Yat-sen University; HE Science Foundation; Young Talents Program of Sun Yat-sen University Cancer Center; Academician Workstation of Jun Ma; Specific Research Fund of the Innovation Platform for Academicians of Hainan Province; Shenzhen Medical Research Fund; Guangdong Basic and Applied Basic Research Foundation.

Authors

Zi-Wei Huang, Zi-Han Wang, Yi Liu, Jia-Yi Shen, Yan-Ling Wu, Zi-An Fang, Dong-Hong Wu, Yi-Zhe Cheng, Jing-Jing Zhang, Xiong Zou, Jun Ma, Jiawei Lv, Shuang Wang, Yu-Pei Chen

×

Loading citation information...
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts